Merus Labs International Inc. (MSLI) Receives Average Recommendation of “Hold” from Analysts
Shares of Merus Labs International Inc. (NASDAQ:MSLI) have received an average recommendation of “Hold” from the twelve analysts that are presently covering the firm. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $4.44.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised Merus Labs International from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 14th. Paradigm Capital reaffirmed a “hold” rating and issued a $1.60 price objective (down previously from $1.75) on shares of Merus Labs International in a research note on Wednesday, October 5th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Merus Labs International in a research note on Friday, August 12th.
Shares of Merus Labs International (NASDAQ:MSLI) traded up 1.24% during trading on Thursday, reaching $0.97. The company’s stock had a trading volume of 12,450 shares. The company has a 50 day moving average of $1.00 and a 200-day moving average of $1.25. Merus Labs International has a 12-month low of $0.92 and a 12-month high of $1.90. The stock’s market cap is $113.49 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/merus-labs-international-inc-msli-receives-average-recommendation-of-hold-from-analysts.html
Merus Labs International (NASDAQ:MSLI) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by $0.03. Merus Labs International had a negative return on equity of 3.41% and a negative net margin of 12.89%. Analysts forecast that Merus Labs International will post ($0.07) EPS for the current year.
Several large investors have recently bought and sold shares of MSLI. Bank of Montreal Can bought a new stake in Merus Labs International during the second quarter valued at about $103,000. Royal Bank of Canada raised its stake in Merus Labs International by 541.4% in the first quarter. Royal Bank of Canada now owns 136,654 shares of the company’s stock valued at $200,000 after buying an additional 115,349 shares during the last quarter. TD Asset Management Inc. raised its stake in Merus Labs International by 8.1% in the second quarter. TD Asset Management Inc. now owns 182,092 shares of the company’s stock valued at $231,000 after buying an additional 13,681 shares during the last quarter. Vertex One Asset Management Inc. raised its stake in Merus Labs International by 57.4% in the second quarter. Vertex One Asset Management Inc. now owns 314,700 shares of the company’s stock valued at $400,000 after buying an additional 114,700 shares during the last quarter. Finally, Guardian Capital LP raised its stake in Merus Labs International by 21.1% in the second quarter. Guardian Capital LP now owns 1,208,400 shares of the company’s stock valued at $1,533,000 after buying an additional 210,500 shares during the last quarter. 25.73% of the stock is owned by institutional investors and hedge funds.
About Merus Labs International
Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.
Receive News & Ratings for Merus Labs International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.